natgillin/translations-raw huggingface dataset:
The apparatus of claim 4, wherein the first engagement mechanism comprises a threaded cavity (60) at the proximal end of the stick (40) and the second engagement mechanism comprises an externally threaded section (50) extending from the lollipop head (10) which releasably engages the threaded cavity of the stick to create the lollipop. 
Uređaj u skladu s patentnim zahtjevom 4, naznačen time što prvi mehanizam za zahvaćanje sadrži šupljinu s navojem (60) na prednjem kraju štapića (40), a drugi mehanizam za zahvaćanje sadrži dio s navojem izvana (50) koji se pruža od glave za lizalicu (10), koji na odvojivi način zahvaća šupljinu s navojem štapića kako bi se načinilo lizalicu.
The apparatus of claim 8, wherein the one or more design elements comprise printed material and/or one or more three dimensional objects affixed to the stick (40). 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što jedan ili više dizajniranih elemenata sadrže otisnuti materijal i/ili jedan ili više trodimenzionalnih objekata pričvršćenih na štapić (40).
The apparatus of any of claims 1 to 10, comprising a plurality of lollipop heads (10) for successively securing to the stick (40) one at a time prior to consumption. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što sadrži više glava za lizalice (10) za uzastopno pričvršćivanje na štapić (40) jednu po jednu prije upotrebe.
for use in prophylaxis and/or treatment of benign prostate hypertrophy. 
za uporabu u prevenciji i/ili liječenju karcinoma prostate.
The compound for use according to anyone of the preceding claims, combined with a compound selected from the group consisting of 5a-reductase inhibitors other than the compounds of claim 1, and anti-androgens. 
Spoj za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se spoj koristi prije, zajedno ili nakon liječenja raka prostate s lijekom izabranim iz grupe koja obuhvaća inhibitore 5a-reduktaze koji nisu spojevi prema zahtjevu 1, i anti-androgene, za kontrolu ginekomastije povezane s takvim liječenjem raka prostate.
The compound for use according to claim 1, wherein the compound is defined by a and c being a single bond, b being a double bond. 
Spoj za uporabu prema zahtjevu 1, gdje je spoj definiran time što su a i c jednostruka veza, b je dvostruka veza.
The compound for use according to anyone of the preceding claims, wherein the compound is used prior to, concurrent with or after prostate cancer treatment with a drug selected from the group consisting of 5a-reductase inhibitors other than the compounds of claim 1, and anti-androgens, for controlling gynecomastia associated with such prostate cancer treatment. 
Spoj za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se spoj koristi prije, zajedno ili nakon liječenja raka prostate s lijekom izabranim iz grupe koja obuhvaća inhibitore 5a-reduktaze koji nisu spojevi prema zahtjevu 1, i anti-androgene, za kontrolu ginekomastije povezane s takvim liječenjem raka prostate.
The pharmaceutical composition for use according to claim 10 or 11 in the form of a topical formulation. 
Farmaceutski oblik za uporabu prema zahtjevu 10 ili 11 u topikalnom obliku.
A process for purifying daptomycin comprising the steps of 
Postupak za pročišćavanje daptomicina koji sadrži korake
loading the solution of step a) onto a reverse phase chromatography column; 
punjenje otopine iz koraka a) u kromatografsku kolonu reverzne faze;
A process for purifying daptomycin containing the steps of 
Postupak za pročišćavanje daptomicina koji sadrži korake
subjecting a fermentation broth comprising daptomycin to one or several clarification steps; 
podvrgavanja fermentacijske smjese koja sadrži daptomicin jednom ili nekoliko koraka bistrenja;
loading the solution of step b) onto a reverse phase chromatography column; 
punjenje otopine iz koraka b) kromatografsku kolonu reverzne faze;
subjecting the resulting solution of step d) to one or several filtration steps; 
podvrgavanje dobivene otopine iz koraka d) jednom ili nekoliko koraka filtriranja;
The process according to any of the preceding claims, characterised in that said amine is used in an amine/acid molar ratio of at least 0.6/1. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se navedeni amin koristi u molarnom odnosu amin/kiselina od najmanje 0,6/1.
The process according to claim 7, characterised in that (R)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid is isolated by filtration following acidification. 
Postupak prema patentnom zahtjevu 7, naznačen time, da se (R)-(-)-3- (karbamoilmetil)-5-metilheksanska kiselina izolira filtriranjem nakon zakiseljavanja.
A process for the preparation of pregabalin ((S)-(+)-3-(aminomethyl)-5-methylhexanoic acid) comprising: 
Postupak za pripremu pregabalin ((S)-(+)-3-(aminometil)-5-metilheksanske kiseline), naznačen time, da sadrži:
reacting 3-(carbamoylmethyl)-5-methylhexanoic acid racemate in a solvent with an amine selected from 1-(1-naphthyl)ethylamine and phenylglycinol, in optically active form, said solvent being selected from ethyl acetate, alcohols, dioxane and mixtures thereof; 
reakciju racemata 3-(karbamoilmetil)-5-metilheksanske kiseline u otapalu s aminom odabranim od 1-(1-naftil)etilamina i fenilglicinola, u optički aktivnom obliku, s tim da se navedeno otapalo odabire od etilacetata, alkohola, dioksana i njihovih smjesa;
separating the two diastereoisomeric salts and recovering the (R)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid from the corresponding salt; 
odvajanje dvije dijastereoizomerne soli i regeneraciju (R)-(-)-3-(karbamoilmetil)-5-metilheksanske kiseline iz odgovarajuće soli;
The process according to claim 12, characterised in that in step (d) the (R)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid is converted into pregabalin by means of a Hoffmann degradation. 
Postupak prema patentnom zahtjevu 12, naznačen time, da se u stupnju (d) (R)-(-)-3-(karbamoilmetil)-5-metilheksanska kiselina pretvori u pregabalin pomoću Hoffmannove pregradnje.
Process for cleaning and sanitizing surgical tools or surgical instruments in general, comprising the use of abrasive cleaning material, emitted under pressure and at high speed against said instruments for abrading and removing the substances that adhere to the surfaces of the same instruments, characterized in that said abrasive cleaning material comprises sodium bicarbonate salts, mixtures of the same. 
Postupak čišćenja i dezinfekcije (sanitarni postupak) kirurških alata ili kirurških instrumenata općenito, obuhvaća uporabu abrazivnog materijala za čišćenje, ispuštenog pod pritiskom i velikom brzinom na te instrumente radi struganja i uklanjanja tvari koje su se primile za površine tih istih instrumenata, naznačen time što taj abrazivni materijal za čišćenje sadrži soli natrijevog bikarbonata i njihove mješavine.
Process (1) according to claim 1, characterized in that said cleaning material is used in the dry state. 
Postupak (1) prema zahtjevu 1, naznačen time što se taj materijal za čišćenje koristi u suhom stanju.
Process according to claim 1, characterized in that said abrasive cleaning material comprises said sodium bicarbonate salts dissolved in water beyond the saturation limit so as to form a solution comprising dissolved and/or undissolved salts, suited to be emitted under pressure and at high speed and projected against the instruments to be cleaned, and wherein said water is or is not heated. 
Postupak prema zahtjevu 1, naznačen time što taj abrazivni materijal za čišćenje sadrži te soli natrijevog bikarbonata otopljene u vodi iznad granice zasićenja tako da se dobije otopina koja sadrži otopljene i/ili neotopljene soli, i prikladna je za ispuštanje pod pritiskom i velikom brzinom na instrumente koje treba očistiti, i pri čemu se ta voda ne zagrijava.
Process according to claims 1, 2 or 3, characterized in that said abrasive cleaning material also comprises one or more further agents with disinfecting and/or biocidal properties. 
Postupak prema zahtjevima 1, 2 ili 3, naznačen time što taj abrazivni materijal za čišćenje sadrži također i jedno ili više dodatnih sredstava s dezinfekcijskim i/ili biocidnim svojstvima.
Device for cleaning and sanitizing surgical instruments according to claims 8, 9, characterized in that said emitter nozzle (U) can be moved in an automated way, and translated along the three spatial directions and/or rotated, so as to direct the jet on the entire surface of the instruments (S) to be cleaned. 
Uređaj za čišćenje i dezinfekciju kirurških instrumenata prema zahtjevima 8, 9, naznačen time što se ispusna mlaznica (U) može automatski pomicati i prenositi duž tri smjera u prostoru i/ili rotirati, tako da se mlaz usmjeri na cijelu površinu instrumenata (S) koji se čiste.
Device for cleaning and sanitizing surgical instruments according to claims 8, 9, 10 or 11, characterized in that it comprises one or more supports (A) for said surgical instruments (S) inside said cabinet (C), suited to constrain the instruments (S) and keep them in the correct position during the sand blasting operation. 
Uređaj za čišćenje i dezinfekciju kirurških instrumenata prema zahtjevima 8, 9, 10 ili 11, naznačen time što obuhvaća jednu ili više potpora (A) za kirurške instrumente (S) unutar kabineta (C), prilagođene da drže instrumente (S) i održavaju ih u ispravnom položaju tijekom postupka pjeskarenja.
Device for cleaning and sanitizing surgical instruments according to claim 12, characterized in that said supports (A) for the instruments (S) to be cleaned can be moved in an automated way, through rotation and/or translation, so as to expose the entire surface of the instrument (S) to the jet of the emitter nozzle (U). 
Uređaj za čišćenje i dezinfekciju kirurških instrumenata prema zahtjevu 12, naznačen time što se te potpore (A) za instrumente (S) koji se čiste mogu pomicati automatski, putem rotacije i/ili prijenosa, tako da se izloži cijela površina instrumenta (S) mlazu iz ispusne mlaznice (U).
Device for cleaning and sanitizing surgical instruments according to claims 8, 9, 10, 11, 12, 13, characterized in that it comprises: means for rinsing and/or blowing on the instrument after the sand blasting operation, a vacuum suction system or a pressure thrust system suited to convey the abrasive material into said cabinet (C) and a filtering system for filtering the air that flows out of the cabinet (C) and recovering the used material for which at least one suitable container is provided. 
Uređaj za čišćenje i dezinfekciju kirurških instrumenata prema zahtjevima 8, 9, 10, 11, 12, 13, naznačen time što obuhvaća: alate za ispiranje i/ili propuhivanje instrumenta nakon postupka pjeskarenja, vakuumski usisni sustav ili potisni tlačni sustav podešen za prijenos abrazivnog materijala u kabinet (C) i sustav filtriranja za filtriranje zraka koji izlazi iz kabineta (C) i povratno dobivanje korištenog materijala za koji je predviđen barem jedan prikladni spremnik.
is C1-C6 alkyl or C1-C6 hydroxyalkyl, C1-C3 alkoxyalkyl, amino(C1-C6)alkyl, where the amino group is optionally substituted with one or two C1-C3 alkyl groups, being said alkyl groups linear or branched; C6-C14 aryl or C6-C14 aryl(C1-C6)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C1-C6 alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C1-C6 alkyl linear or branched; its optically active forms such as enantiomers, diastereomers and its racemate forms, and pharmaceutically acceptable salts thereof; with the proviso that R4, R6 and R8 are not all H at the same time. 
je C1-C6 alkil ili C1-C6 hidroksialkil, C1-C3 alkoksialkil, amino(C1-C6)alkil, gdje je amino skupina izborno supstituirana s jednom ili dvije C1-C3 alkilne skupine, gdje su navedene alkilne skupine nerazgranate ili razgranate; C6-C14 aril ili C6-C14 aril(C1-C6)alkil, gdje je arilna skupina izborno supstituirana s jednim ili više supstituenata, bilo istih ili različitih, koje se bira iz skupine koju čine halogen, hidroksi, nerazgranati ili razgranati zasićeni ili nezasićeni C1-C6 alkoksi, amino, mono- ili disupstituiran s C1-C6 alkil nerazgranati ili razgranati; njegovi optički aktivni oblici, poput enantiomera, dijastereomera i njegovih racemičnih oblika, te njegove farmaceutski prihvatljive soli; uz uvjet da R4, R6 i R8 nisu svi istodobno H.
The compound according to claim 7 for use in the treatment of a pathological state for which the modulation of A2A activity would result in improving the health of the patient. 
Spoj u skladu s patentnim zahtjevom 7, naznačen time što je namijenjen upotrebi u liječenju patološkog stanja kod kojeg bi moduliranje aktivnosti A2A dovelo do poboljšanja zdravlja pacijenta.
The compound for use according to claim 9, wherein said motor disorder is Parkinson's disease, Alzheimer's disease, Huntington's disease, Wilson's disease or Hallervorden-Spatz disease, 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je navedeni motorički poremećaj Parkinsonova bolest, Alzheimerova bolest, Huntingtonova bolest, Wilsonova bolest ili Hallervorden-Spatzova bolest.
Process for synthesizing compounds of claim 1, wherein R2 is a group of formula R9-(CHR8)p-(CR6R7)m-(CR4R5)n-; 
Postupak sinteze spojeva u skladu s patentnim zahtjevom 1, gdje je skupina formule R9-(CHR8)p-(CR6R7)m-(CR4R5)n-;
R6b and R6c are at any occurrence independently both H or when taken together with the carbon atom to which they are attached to form a 1,3- dioxane group optionally substituted by two or more methyl groups with at least one of the occurrence being a 1,3-dioxane group optionally substituted by two or more methyl groups; 
b i R6c su svaki put neovisno istodobno H ili, kada ih se uzima zajedno s atomom ugljika na kojeg su vezani, tvore 1,3-dioksansku skupinu, izborno supstituiranu s dvije ili više metilnih skupina, gdje je najmanje jedan od slučajeva 1,3-dioksanska skupina, izborno supstituirana s dvije ili više metilnih skupina;
in the presence of a Fe(acac)3 in an aprotic solvent such as THF or NMP at a temperature ranging from 0°C to RT. 
u prisutnosti Fe(acac)3 u neprotonskom otapalu, poput THF ili NMP, na rasponu temperatura od 0 °C do sobne temperature.
Process for synthesizing compounds of claim 1, comprising the reaction between a compound of formula II as in claim 14, with a compound of formula VIII wherein 
Postupak sinteze spojeva u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u reakciji između spoja formule II u skladu s patentnim zahtjevom 14 i spoja formule VIII [image], gdje
in the presence of Hermann's catalyst and sodium acetate in a polar solvent such as NMP. 
u prisutnosti Hermannovog katalizatora i natrijevog acetata u polarnom otapalu, poput NMP.
CCI-779 for use according to Claim 1, wherein the papillary renal cell carcinoma is selected from hereditary type I papillary renal cell carcinoma, hereditary type II papillary renal cell carcinoma and sporadic papillary renal cell carcinoma. 
CCI-779, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se uznapredovali papilarni karcinom bubrežnih stanica bira između nasljednog papilarnog karcinoma bubrežnih stanica tip I, nasljednog papilarnog karcinoma bubrežnih stanica tip II i sporadičnog papilarnog karcinoma bubrežnih stanica.
CCI-779 for use according to any of Claims 1 to 9, further comprising a further active agent, provided that the further active agent is not an interferon. 
CCI-779, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što dodatno sadrži dodatno aktivno sredstvo, uz uvjet da dodatno aktivno sredstvo nije interferon.
for use in the prophylaxis and/or the treatment of cellulite. 
za uporabu u prevenciji i/ili liječenju karcinoma prostate.
The compound for use according to claim 10 in the form of a topical formulation. 
Farmaceutski oblik za uporabu prema zahtjevu 10 ili 11 u topikalnom obliku.
The method according to any of claims 1 to 11, wherein the CCI-779 is the sole anti-neoplastic agent in the regimen. 
CCI-779, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je CCI-779 jedino antineoplastično sredstvo u režimu.
The method or use as claimed in any of Claims 1 to 3, wherein the thromboembolic disorder is ST Segment Elevation Myocardial Infarction (STEM), Non ST Segment Elevation Myocardial Infarction (NSTEMI), unstable angina, reocclusion after angioplasty or aortocoronary bypass, pulmonary embolisms, deep vein thromboses or stroke. 
Upotreba prema zahtjevu 1, naznačena time da tromboembolijskog poremećaja je infarkt miokarda sa elevacijom ST-segmenta (STEMI), infarkt miokarda bez elevacije ST-segmenta (NSTEMI), nestabilna angina, ponovno začepljenje nakon angioplastike ili aortokoronarne premosnice, plućna embolija, duboka venska tromboza ili moždani udar.
Wind system (1) according to claim 2, characterised in that said spring is compressed due to said tension of said rope (4). 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da se spomenuti spojler pokreće preko sustava sa samostalnim napajanjem.
A mushroom production process comprising the steps of: 
Postupak proizvodnje gljiva koji sadrži korake:
preparing a mushroom growing shed (3) with at least one bed of mushroom compost; 
priprema prostora za uzgoj gljiva (3) s barem jednom gredicom komposta za gljive;
supplying heat to the mushroom growing shed (3); 
dovođenje topline u prostor za uzgoj gljiva (3);
harvesting the mushrooms; removing the spent mushroom compost from the mushroom growing shed (3); 
berba gljiva; uklanjanje potrošenog komposta za gljive iz prostora za uzgoj gljiva (3):
combusting the spent mushroom compost in an energy conversion system (29); 
spaljivanje potrošenog komposta za gljive u sustavu za konverziju energije (29);
and, the fluidised bed unit (37) comprises a plurality of temperature sensors which are arranged in the fluidised bed unit (37) to closely monitor the temperature of the fluidised bed in the fluidised bed unit (37); 
i, jedinica s fluidiziranim slojem (37) sadrži više temperaturnih senzora koji su uklopljeni u jedinicu s fluidiziranim slojem (37) radi pomnijeg praćenja temperature fluidiziranog sloja u jedinici s fluidiziranim slojem (37);
A process as claimed in claim 1 comprising the steps of: initially storing spent mushroom compost in an open storage area (7) adjacent the fluidised bed unit (37); and 
početno spremanje komposta gljiva u otvoreni skladišni prostor (7) susjedan jedinici s fluidiziranim slojem (37); i povlačenje zraka radi opskrbe jedinice s fluidiziranim slojem (37) iz gornjeg dijela otvorenog skladišnog prostora.
A process as claimed in claim 5 comprising the step of delivering the heated liquid to a radiator element (15) located inside the mushroom growing shed (3). 
Postupak sukladno Zahtjevu 5 koji sadrži korak isporuke zagrijane tekućine u element za zagrijavanje (15) koji se nalazi unutar prostora za uzgoj gljiva (3).
A process as claimed in claim 6 comprising the step of transferring the heated liquid to a buffer tank (79) prior to delivery to the radiator element (15). 
Postupak sukladno Zahtjevu 6 koji sadrži korak prijenosa zagrijane tekućine u sabirni spremnik (79), prije isporuke u element za zagrijavanje (15).
A process as claimed in claims 5 or 6 comprising the step of monitoring the temperature in the mushroom growing shed (3) and controlling the temperature of the environment in the mushroom growing shed (3) by regulating the flow of heated liquid to the radiator element (15). 
Postupak sukladno Zahtjevima 5 ili 6, koji obuhvaća korak praćenja temperature prostora za uzgoj gljiva (3), te kontrolu temperature okoline u prostoru za uzgoj gljiva (3) reguliranjem protoka ugrijane tekućine u element za zagrijavanje (15).
A process as claimed in any preceding claim comprising the step of, after removing the spent mushroom compost from the mushroom growing shed (3), delivering the spent mushroom compost to a fuel storage area (7) for subsequent combustion.. 
Postupak sukladno bilo kojem od prethodnih Zahtjeva koji sadrži korak u kojem se, nakon uklanjanja komposta od korištenih gljiva iz prostora za uzgoj gljiva (3), kompost od korištenih gljiva dostavlja u prostor za skladištenje goriva (7) radi kasnijeg spaljivanja.
A process as claimed in claim 12 in which the fuel storage area (7) comprises an open storage area adjacent the combustion apparatus. 
Postupak sukladno Zahtjevu 12 u kojem se prostor za skladištenje goriva (7) sastoji od otvorenog skladišnog prostora susjednog aparatu za spaljivanje.
The compound of claim 1, wherein the compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je spoj odabran iz skupine koju čine:
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutski prihvatljiv nosač i spoj prema bilo kojem od zahtjeva 1 - 5, ili njegovu farmaceutski prihvatljivu sol.
The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, for use in treating or preventing multiple sclerosis, an autoimmune disease, a chronic inflammatory disorder, asthma, an inflammatory neuropathy, arthritis, transplantation rejection, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, an ischemia-reperfusion injury, a solid tumour, tumour metastasis, a disease associated with angiogenesis, a vascular disease, a pain condition, an acute viral disease, an inflammatory bowel condition, insulin dependent diabetes, or non-insulin dependent diabetes. 
Spoj prema bilo kojem od zahtjeva 1 - 5, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da se upotrebljava u liječenju ili prevenciji sljedećih stanja: multipla skleroza, autoimuna bolest, kronični upalni poremećaj, astma, upalna neuropatija, artritis, odbijanje transplantata, Crohnova bolest, ulcerativni kolitis, lupus eritematoza, psorijaza, ishemijska-reperfuzijska ozljeda, čvrsti tumor, tumorske metastaze, bolest povezana s angiogenezom, vaskularna bolest, stanje bolova, akutno virusno oboljenje, upalno stanje crijeva, dijabetes ovisan o inzulinu, ili dijabetes neovisan o inzulinu.
The compound for use according to claim 7, or a pharmaceutically acceptable salt thereof, wherein the pathological condition is neuropathic pain or an autoimmune disease. 
Spoj za uporabu prema zahtjevu 7, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da patološko stanje su neuropatski bolovi ili je to autoimuna bolest.
The compound for use according to claim 7, or a pharmaceutically acceptable salt thereof, wherein the autoimmune disease is uveitis, type I diabetes, rheumatoid arthritis, inflammatory bowel diseases, or multiple sclerosis. 
Spoj za uporabu prema zahtjevu 7, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da autoimuna bolest je uveitis, dijabetes tipa 1, reumatoidni artritis, upalna bolest crijeva ili multipla skleroza.
The compound for use according to claim 7, or a pharmaceutically acceptable salt thereof, wherein the use in treating or preventing further includes use of a drug selected from the group consisting of: a corticosteroid, a bronchodilator, an antiasthmatic, an antiinflammatory, an antirheumatic, an immunosuppressant, an antimetabolite, an immunomodulator, an antipsoriatic, and an antidiabetic. 
Spoj za uporabu prema zahtjevu 7, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da uporaba u liječenju ili prevenciji nadalje uključuje uporabu lijeka odabranog iz skupine koju čine: kortikosteroid, bronhodilator, antiastmatik, protuupalno sredstvo, antireumatik, imunosupresiv, antimetabolit, imunomodulator, antipsorijatik, i antidijabetik.
adding (212) anhydrous ammonia (18) to said phosphorus-loaded water immiscible liquid phase (14); 
dodavanje (212) bezvodnog amonijaka (18) toj tekućoj fazi (14) koja je napunjena fosforom i ne miješa se s vodom;